Where Does Axatilimab Fit in the Treatment Lineup?
Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.
Video content above is prompted by the following questions:
- What were the key findings from the AGAVE-201 trial presented at the 2023 ASH meeting?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
Recent Videos
Related Content
